Characterisation of the Circulating Transcriptomic Landscape in Inflammatory Bowel Disease Provides Evidence for Dysregulation of Multiple Transcription Factors Including NFE2, SPI1, CEBPB, and IRF2
Authors: Nowak Jan K , Adams Alex T , Kalla Rahul , Lindstrøm Jonas C , Vatn Simen , Bergemalm Daniel , Keita Åsa V , Gomollón Fernando , Jahnsen Jørgen , Vatn Morten H , Ricanek Petr , Ostrowski Jerzy , Walkowiak Jaroslaw , Halfvarson Jonas , Satsangi Jack ,   IBD Character Consortium, Andersson Erik , Arnott Ian D , Bayes Monica , Bonfiglio Ferdinando , Boyapati Ray K , Carstens Adam , Casén Christina , Ciemniejewska Ewa , D’Amato Mauro , A. Dahl Fredrik , Detlie Trond Espen , Drummond Hazel E , Ekeland Gunn S , Ekman Daniel , Frengen Anna B , Gullberg Mats , Gut Ivo G , Gut Marta , Heath Simon C , Hjelm Fredrik , Hjortswang Henrik , Ho Gwo-Tzer , Jonkers Daisy , Kennedy Nicholas A , Lees Charles W , Lindahl Torbjørn , Lindqvist Mårten , Merkel Angelika , Modig Eddie , Moen Aina E F , Nilsen Hilde , Nimmo Elaine R , Noble Colin L , Nordberg Niklas , O’Leary Kate R , Ocklind Anette , Olbjørn Christine , Pettersson Erik , Pierik Marieke , Poncelet Dominique , Repsilber Dirk , Sabatel Céline , Schoemans Renaud , Shand Alan G , Söderholm Johan D , Sølvernes Janne , Sundell Mikael , Tannæs Tone M , Törkvist Leif , Veillard Anne-Clémence , Ventham Nicholas T , Wilson David C , You Panpan 
Published: February 2022

Aim

To assess the pathobiological and translational importance of whole-blood transcriptomic analysis in inflammatory bowel disease [IBD].

Methods

We analysed whole-blood expression profiles from paired-end sequencing in a discovery cohort of 590 Europeans recruited across six countries in the IBD Character initiative (newly diagnosed patients with Crohn’s disease [CD; n = 156], ulcerative colitis [UC; n = 167], and controls [n = 267]), exploring differential expression [DESeq2], co-expression networks [WGCNA], and transcription factor involvement [EPEE, ChEA, DoRothEA]. Findings were validated by analysis of an independent replication cohort [99 CD, 100 UC, 95 controls]. In the discovery cohort, we also defined baseline expression correlates of future treatment escalation using cross-validated elastic-net and random forest modelling, along with a pragmatic ratio detection procedure.

Results

Disease-specific transcriptomes were defined in IBD [8697 transcripts], CD [7152], and UC [8521], with the most highly significant changes in single genes, including CD177 (log2-fold change [LFC] = 4.63, p = 4.05 × 10-118), MCEMP1 [LFC = 2.45, p = 7.37 × 10-109], and S100A12 [LFC = 2.31, p = 2.15 × 10-93]. Significantly over-represented pathways included IL-1 [p = 1.58 × 10-11], IL-4, and IL-13 [p = 8.96 × 10-9]. Highly concordant results were obtained using multiple regulatory activity inference tools applied to the discovery and replication cohorts. These analyses demonstrated central roles in IBD for the transcription factors NFE2, SPI1 [PU.1], CEBPB, and IRF2, all regulators of cytokine signalling, based on a consistent signal across cohorts and transcription factor ranking methods. A number of simple transcriptome-based models were associated with the need for treatment escalation, including the binary CLEC5A/CDH2 expression ratio in UC (hazard ratio = 23.4, 95% confidence interval [CI] 5.3–102.0).

Conclusions

Transcriptomic analysis has allowed for a detailed characterisation of IBD pathobiology, with important potential translational implications.